Article

Status epilepticus.

Continuum (Minneapolis, Minn.) 06/2013; 19(3 Epilepsy):767-94. DOI: 10.1212/01.CON.0000431395.16229.5a
Source: PubMed

ABSTRACT Purpose of Review: This review presents the state of the art in the diagnosis and management of status epilepticus.Recent Findings: In addition to general background, this article presents the most recent findings regarding the diagnosis and treatment of status epilepticus, including the results of the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) and the available data on the use of newer antiepileptic and anesthetic drugs in the treatment of refractory status epilepticus. It also presents available guidelines such as those from the Neurocritical Care Society.Summary: Despite recent advances, the management of status epilepticus remains a challenge. Rapid treatment, a written treatment protocol, early consideration of nonconvulsive seizures, and avoiding overtreatment and medical complications are the keys to successful management. This article summarizes the current evidence and guidelines.

1 Follower
 · 
172 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-convulsive status epilepticus (NCSE) is status epilepticus without obvious tonic-clonic activity. Patients with NCSE have altered mental state. An EEG is needed to confirm the diagnosis, but obtaining an EEG on every patient with altered mental state is not practical. To determine whether clinical features could be used to predict which patients were more likely to be in NCSE and thus in need of an urgent EEG. Over a six month period, all patients for whom an urgent EEG was ordered to identify NCSE were enrolled. Neurology residents examined the patients and filled out a questionnaire without knowledge of the EEG results. The patients were divided into two groups, NCSE and non-NCSE, depending on the EEG result. The clinical features were compared between the two groups. The sensitivity and specificity of the features were calculated. 48 patients were enrolled, 12 in NCSE and 36 not in NCSE. Remote risk factors for seizures, severely impaired mental state, and ocular movement abnormalities were seen significantly more often in the NCSE group. The combined sensitivity of remote risk factors for seizures and ocular movement abnormalities was 100%. There are certain clinical features that are more likely to be present in patients in NCSE compared with other types of encephalopathy. Either remote risk factors for seizures or ocular movement abnormalities were seen in all patients in NCSE. These features may be used to select which patients should have an urgent EEG.
    Journal of Neurology Neurosurgery & Psychiatry 03/2003; 74(2):189-91. DOI:10.1136/jnnp.74.2.189 · 5.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the incidence, predictors, and timing of nonconvulsive seizures (NCSz) during continuous electroencephalographic monitoring (cEEG) in critically ill children. We identified critically ill children who underwent cEEG during a 4-year period. Multivariate logistic regression analysis was performed to determine variables associated with NCSz. Among 117 monitored children, 44% had seizures on cEEG and 39% had NCSz. The majority of patients with seizures (75%) had purely NCSz, and 23% of patients had status epilepticus, which was purely nonconvulsive in 89% of cases. Seizures occurred immediately on cEEG initiation in 15%, within 1 hour in 50%, and within 24 hours in 80%. Those with clinical seizures prior to cEEG were more likely to have NCSz on cEEG (83%) than those without prior seizures (17%). On multivariate analysis, NCSz were associated with periodic lateralized epileptiform discharges and absence of background reactivity. Seizures, the majority being NCSz, are common during cEEG in critically ill children (seen in 44% of patients). Half are detected in the first hour of recording, whereas 20% are not detected until after more than 24 hours of recording. Nonconvulsive seizures are associated with periodic lateralized epileptiform discharges and absence of reactivity on cEEG. This study confirms the importance of prolonged cEEG for critically ill children as a means to detect NCSz.
    JAMA Neurology 01/2007; 63(12):1750-5. DOI:10.1001/archneur.63.12.1750 · 7.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Early termination of prolonged seizures with intravenous administration of benzodiazepines improves outcomes. For faster and more reliable administration, paramedics increasingly use an intramuscular route. This double-blind, randomized, noninferiority trial compared the efficacy of intramuscular midazolam with that of intravenous lorazepam for children and adults in status epilepticus treated by paramedics. Subjects whose convulsions had persisted for more than 5 minutes and who were still convulsing after paramedics arrived were given the study medication by either intramuscular autoinjector or intravenous infusion. The primary outcome was absence of seizures at the time of arrival in the emergency department without the need for rescue therapy. Secondary outcomes included endotracheal intubation, recurrent seizures, and timing of treatment relative to the cessation of convulsive seizures. This trial tested the hypothesis that intramuscular midazolam was noninferior to intravenous lorazepam by a margin of 10 percentage points. At the time of arrival in the emergency department, seizures were absent without rescue therapy in 329 of 448 subjects (73.4%) in the intramuscular-midazolam group and in 282 of 445 (63.4%) in the intravenous-lorazepam group (absolute difference, 10 percentage points; 95% confidence interval, 4.0 to 16.1; P<0.001 for both noninferiority and superiority). The two treatment groups were similar with respect to need for endotracheal intubation (14.1% of subjects with intramuscular midazolam and 14.4% with intravenous lorazepam) and recurrence of seizures (11.4% and 10.6%, respectively). Among subjects whose seizures ceased before arrival in the emergency department, the median times to active treatment were 1.2 minutes in the intramuscular-midazolam group and 4.8 minutes in the intravenous-lorazepam group, with corresponding median times from active treatment to cessation of convulsions of 3.3 minutes and 1.6 minutes. Adverse-event rates were similar in the two groups. For subjects in status epilepticus, intramuscular midazolam is at least as safe and effective as intravenous lorazepam for prehospital seizure cessation. (Funded by the National Institute of Neurological Disorders and Stroke and others; ClinicalTrials.gov number, ClinicalTrials.gov NCT00809146.).
    New England Journal of Medicine 02/2012; 366(7):591-600. DOI:10.1056/NEJMoa1107494 · 54.42 Impact Factor

Full-text

Download
355 Downloads
Available from
May 30, 2014